NTRK2 and breast cancer: Interestingly, from a clinical perspective, stratifying patients based on either the expression levels of NTRK2 (TRKB) or FOXO1 is predictive of a good prognosis (overall survival) in breast cancer, similar to prognosis based on PR expression (Figures 6F, G).